Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
Nagai M, Moriyama M, Ichinohe T. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. MBio 2021, 12: 10.1128/mbio.01598-21. PMID: 34399617, PMCID: PMC8406166, DOI: 10.1128/mbio.01598-21.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralBacteriaCell LineChlorocebus aethiopsCOVID-19COVID-19 VaccinesDogsHemagglutinin Glycoproteins, Influenza VirusImmunity, MucosalInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CMyeloid Differentiation Factor 88Nasal MucosaOrthomyxoviridae InfectionsPathogen-Associated Molecular Pattern MoleculesSARS-CoV-2VaccinationVero CellsConceptsInfluenza virus infectionVirus-specific adaptive immunityVaccine-specific antibody responseVirus-specific antibody responsesAntibody responseMyD88-dependent mannerVirus infectionHealthy human volunteersPathogen-associated molecular patternsImmune responseNasal bacteriaOral bacteriaCommensal bacteriaIntranasal supplementationHA vaccineVaccine protectsIntranasal vaccineIntranasal administrationIntranasal applicationAdaptive immunityOral cavityAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere acute respiratory syndrome coronavirus 2Influenza virus hemagglutinin vaccine